Pharmaceutical Factory Insurance Malaysia: GMP GDP Coverage Guide 2026

A single contamination event at a pharmaceutical factory can destroy an entire production batch worth millions of ringgit. Add NPRA-mandated product recalls, cold chain failures during Malaysia's 35°C heat, and the cost of rebuilding a compromised cleanroom, and you're looking at losses that can shut down a pharma operation permanently.

This guide breaks down every insurance coverage a Malaysian pharmaceutical manufacturer needs, from property and machinery to product contamination and regulatory liability.

This guide covers:

• Essential insurance products for pharma factories in Malaysia
• GMP and GDP compliance risks that trigger insurance claims
• Product contamination and recall coverage
• Cold chain and cleanroom-specific insurance considerations
• Premium factors and coverage limits for pharma manufacturers
• How to structure a complete pharma insurance programme

Why Pharmaceutical Factories Need Specialised Insurance

Pharmaceutical manufacturing isn't like general manufacturing. You're operating in controlled environments where a 2°C temperature deviation can destroy an entire inventory of biologic products. Your raw materials include active pharmaceutical ingredients (APIs) worth RM50,000 to RM500,000 per kilogramme. And every product you make is subject to NPRA regulatory oversight.

Standard factory insurance policies don't account for these realities. A generic Industrial All Risks (IAR) policy covers fire and machinery breakdown, but it won't cover the cost of decontaminating a cleanroom after a microbial breach. It won't pay for the NPRA-mandated recall of a batch that left your facility before you discovered the contamination.

Malaysian pharma factories face a unique risk profile that demands layered, specialised coverage.

Risk Category	Pharma-Specific Exposure	General Factory Exposure
Property Damage	Cleanroom contamination, API spoilage, cold chain failure	Fire, flood, structural damage
Product Liability	Adverse drug reactions, contaminated medication reaching patients	Defective product causing injury
Regulatory Risk	NPRA licence suspension, GMP non-compliance, mandatory recall	DOSH inspection, environmental fines
Business Interruption	Re-validation of cleanrooms (weeks to months), API re-sourcing delays	Equipment repair downtime
Stock Value	High-value APIs, temperature-sensitive biologics, finished goods with expiry dates	Raw materials, finished goods
Equipment	HVAC systems, tablet presses, HPLC equipment, autoclaves, lyophilizers	General production machinery

Regulatory Framework: GMP, GDP, and NPRA Requirements

Understanding the regulatory landscape helps you identify where insurance gaps exist. Malaysia's pharmaceutical manufacturing is governed by multiple overlapping regulatory frameworks, and non-compliance with any of them creates financial exposure.

Good Manufacturing Practice (GMP)

GMP compliance is enforced by NPRA under the Control of Drugs and Cosmetics Regulations 1984. Every pharmaceutical manufacturer in Malaysia must hold a valid Manufacturer's Licence issued by NPRA. The licence requires demonstrated GMP compliance, and NPRA conducts periodic inspections to verify ongoing adherence.

GMP failures don't just result in fines. They can trigger product recalls, licence suspension, and in severe cases, criminal prosecution. Each of these outcomes creates insurance-relevant financial exposure.

GMP Requirement	Insurance Implication	Coverage Type Needed
Cleanroom environment control (Class 100 to Class 100,000)	HVAC failure causes batch contamination	Machinery Breakdown + Stock Throughput
Temperature and humidity monitoring	Excursion destroys temperature-sensitive products	Stock Deterioration / Cold Chain Coverage
Water system validation (WFI, purified water)	Water system contamination halts production	Business Interruption + Machinery Breakdown
Batch record documentation	Documentation failure triggers recall of affected batches	Product Recall Insurance
Equipment qualification (IQ/OQ/PQ)	Unqualified equipment produces non-conforming product	Product Liability + CGL
Stability testing (Zone IVB: 30°C/75% RH)	Stability failure post-release triggers market withdrawal	Product Recall + Product Liability

Good Distribution Practice (GDP)

GDP governs the storage and distribution of pharmaceutical products after manufacturing. For pharma factories with on-site warehousing or distribution operations, GDP compliance adds another layer of risk. Temperature mapping of storage areas, transport vehicle qualification, and cold chain integrity are all GDP requirements that create insurable exposures.

A GDP failure in your warehouse can compromise products that passed every GMP test during manufacturing. Your insurance programme needs to account for both manufacturing and distribution risks.

Essential Insurance Products for Pharma Factories

A complete pharmaceutical factory insurance programme requires multiple layered policies. No single product covers everything. Here's what you need and why.

Insurance Product	What It Covers	Pharma Relevance	Priority
Industrial All Risks (IAR)	Building, machinery, stock on all-risks basis	Core property protection for factory and equipment	Essential
Machinery Breakdown	Sudden mechanical/electrical failure	HVAC, tablet presses, autoclaves, packaging lines	Essential
Machinery Loss of Profits (MLOP)	Revenue loss during machinery repair	Cleanroom re-validation can take 2-8 weeks	Essential
Business Interruption	Gross profit loss from insured property damage	NPRA shutdown orders, decontamination periods	Essential
CGL Insurance	Third-party bodily injury, property damage	Visitor injuries, chemical spills affecting neighbours	Essential
Product Liability	Claims from defective products causing harm	Adverse drug reactions, contaminated medication	Essential
Product Recall / Contamination	Recall costs, replacement, business loss	NPRA-mandated recalls, voluntary withdrawals	Highly Recommended
Boiler & Pressure Vessel	Explosion, collapse of pressurised equipment	Autoclaves, steam boilers, compressed gas systems	Essential (if applicable)
Electronic Equipment (EEI)	Damage to sensitive electronic systems	HPLC, mass spectrometers, QC lab equipment	Recommended
Workmen Compensation	Employee injury, occupational disease	Chemical exposure, repetitive strain, cleanroom hazards	Mandatory

Property and Machinery Coverage for Pharma Facilities

The foundation of any pharma factory insurance programme starts with property and machinery protection. But pharma facilities have equipment and assets that require special consideration during policy placement.

High-Value Equipment Requiring Dedicated Coverage

Pharmaceutical equipment is significantly more expensive than general manufacturing equipment. A single HPLC system costs RM200,000 to RM800,000. A tablet compression machine runs RM500,000 to RM3 million. These aren't items you can replace off the shelf; lead times for specialised pharma equipment can stretch to 6-12 months.

Your Machinery Breakdown policy needs adequate sum insured values that reflect replacement costs, not depreciated book values. And your MLOP coverage needs an indemnity period long enough to cover the re-ordering, installation, and re-qualification process.

Equipment Type	Typical Cost Range (RM)	Replacement Lead Time	Key Insurance Consideration
HVAC / AHU System (cleanroom)	RM500,000 - RM5,000,000	3 - 6 months	Failure contaminates entire production area
Tablet Press / Compression Machine	RM500,000 - RM3,000,000	4 - 8 months	Requires IQ/OQ/PQ after replacement
HPLC / Mass Spectrometer (QC Lab)	RM200,000 - RM800,000	2 - 4 months	Without QC lab, no batch release possible
Autoclave / Steriliser	RM300,000 - RM2,000,000	3 - 6 months	BPV coverage may be required
Water for Injection (WFI) System	RM1,000,000 - RM5,000,000	4 - 8 months	Contamination halts all injectable production
Lyophilizer (Freeze Dryer)	RM2,000,000 - RM10,000,000	6 - 12 months	Single-source for some biologic products
Blister Packaging Line	RM400,000 - RM2,000,000	3 - 5 months	Packaging failure = labelling recall risk

Cleanroom Reinstatement Costs

Here's something most generic factory policies miss: cleanroom reinstatement. If fire, flood, or contamination damages your cleanroom, you don't just repair the walls and floor. You need to rebuild to GMP standards, re-qualify HVAC systems, run environmental monitoring for weeks, and get NPRA re-approval before resuming production.

A Class 100 (ISO 5) cleanroom costs RM3,000 to RM8,000 per square metre to build. Reinstatement after damage can cost 20-40% more due to emergency procurement and expedited qualification. Make sure your IAR policy's sum insured accounts for reinstatement to GMP-compliant standards, not just basic building repair.

Product Contamination and Recall Insurance

This is where pharma factories diverge most sharply from general manufacturing. A contaminated batch of tablets that reaches pharmacies across Malaysia can generate recall costs in the millions, plus legal liability if patients are harmed.

What Product Recall Insurance Covers

Product recall insurance is a standalone policy, separate from your CGL or product liability cover. It specifically addresses the logistics and financial impact of removing a product from the market.

Coverage Component	What It Pays For	Pharma Example
Recall Costs	Logistics of retrieving products from distributors, pharmacies, hospitals	Collecting contaminated tablets from 500+ retail pharmacies nationwide
Notification Costs	Public announcements, media placements, direct customer communications	NPRA-mandated public recall notice across media channels
Product Destruction	Safe disposal of recalled products	Incineration of contaminated pharmaceutical products
Replacement Costs	Manufacturing and distributing replacement products	Re-manufacturing and re-distributing compliant batch
Loss of Gross Profit	Revenue loss during recall period (typically up to 12-18 months)	Hospital contracts lost while production line is shut down
Crisis Management	PR consultants, crisis response specialists	Managing media coverage and stakeholder communications
Laboratory Analysis	Testing to identify contamination source and scope	Root cause investigation across multiple batch records

NPRA Recall Classifications

NPRA classifies product recalls into three categories based on severity. The classification determines the urgency and scope of the recall, which directly affects cost.

NPRA Recall Class	Severity	Description	Typical Insurance Impact
Class I	Critical	Product may cause serious health consequences or death	Highest cost; immediate nationwide recall required, plus product liability claims
Class II	Major	Product may cause temporary or medically reversible adverse health consequences	Moderate to high cost; recall from all distribution levels
Class III	Minor	Product unlikely to cause adverse health consequences but violates regulations	Lower cost; may be limited to wholesale/distributor level

Cold Chain and Temperature-Sensitive Storage Risks

Malaysia's tropical climate makes cold chain management a constant challenge for pharma manufacturers. Average ambient temperatures of 27-35°C mean your cold storage and cold chain systems are working harder than facilities in temperate countries. Power outages, compressor failures, and even brief door-seal malfunctions can push temperatures beyond acceptable ranges.

Temperature Excursion Scenarios

A temperature excursion doesn't just damage the affected stock. Under GMP rules, any product exposed to out-of-specification conditions must be quarantined, tested, and potentially destroyed. If the excursion affected products already distributed, you may face a recall.

Storage Condition	Temperature Range	Common Products	Risk of Excursion
Controlled Room Temperature	20°C - 25°C	Tablets, capsules, syrups	Accelerated degradation, potency loss
Refrigerated	2°C - 8°C	Vaccines, insulin, biologics	Complete loss of efficacy, patient safety risk
Frozen	-20°C to -10°C	Certain APIs, reference standards	Molecular degradation, unusable product
Ultra-Cold	-80°C to -60°C	mRNA products, cell therapies	Total product loss within hours of excursion

Standard property insurance typically excludes stock deterioration from temperature change. You need specific stock deterioration or cold storage coverage that explicitly addresses refrigeration breakdown, power failure, and accidental temperature excursion.

Product Liability for Pharmaceutical Manufacturers

Product liability is arguably the highest-severity risk for pharma manufacturers. Unlike a defective construction product that might damage a building, a defective pharmaceutical product can harm or kill people. Claims can come from individual patients, hospitals, government health agencies, or class-action lawsuits.

Product Liability vs CGL: Know the Difference

Many manufacturers assume their CGL policy covers product liability. It does, but only partially. CGL provides "Products-Completed Operations" coverage as a standard extension, but the limits are shared with all other CGL claims. For a pharma manufacturer, a single adverse drug reaction incident could exhaust your entire CGL limit.

Feature	CGL (Products-Completed Ops)	Standalone Product Liability
Limit	Shared with all CGL claims	Dedicated limit for product claims only
Coverage Scope	Bodily injury and property damage from products	Broader; may include recall costs and defence
Defence Costs	Within limit (erodes payout capacity)	Can be in addition to limit
Recall Trigger	Not covered	May include first-party recall costs
Recommended For	Low-risk products, small manufacturers	All pharmaceutical manufacturers

Business Interruption: The Hidden Cost Multiplier

Business interruption (BI) is where pharma factory losses escalate beyond what most operators expect. In general manufacturing, a fire might shut you down for 2-3 months while you rebuild. In pharma manufacturing, the same fire could mean 6-12 months of downtime because you need to not only rebuild but re-qualify everything to GMP standards before NPRA allows you to resume production.

Pharma-Specific BI Timeline

Phase	Duration	Activities
1. Damage Assessment	1 - 2 weeks	Loss adjuster inspection, contamination assessment, scope of damage
2. Physical Repair / Rebuild	2 - 6 months	Construction, cleanroom rebuild, equipment replacement
3. Equipment Qualification	1 - 3 months	IQ/OQ/PQ for all replaced equipment, HVAC validation
4. Process Validation	1 - 2 months	3 consecutive validation batches per product, cleaning validation
5. NPRA Inspection	1 - 2 months	GMP re-inspection, corrective action verification, licence reinstatement
6. Commercial Restart	2 - 4 weeks	Stability testing, batch release, re-establishing supply agreements
Total Potential Downtime	6 - 15 months	Physical + GMP re-qualification + regulatory approval

The takeaway: your BI indemnity period needs to be at least 18-24 months for a pharma factory, compared to 12 months that might be adequate for general manufacturing. If your policy only covers 12 months and your GMP re-qualification takes 14 months, you're absorbing the last 2 months of lost revenue yourself.

Premium Factors for Pharmaceutical Factory Insurance

Pharma factory premiums tend to be higher than general manufacturing due to the concentration of high-value assets, regulatory complexity, and contamination risk. Understanding what drives your premium helps you manage costs without sacrificing critical coverage.

Factor	Impact on Premium	How to Improve
Product type (OTC vs prescription vs biologics)	High; biologics attract highest premiums	Demonstrate robust QC and batch testing protocols
GMP compliance history	High; clean inspection records reduce premium	Maintain consistent NPRA audit scores
Claims history	Very high; any recall history significantly increases premium	Invest in preventive quality systems (CAPA, change control)
Sum insured (property + stock)	Proportional; higher values = higher premium	Accurate valuations prevent overpayment; avoid underinsurance
Fire protection systems	Moderate; sprinklers and detection reduce premium	Install automatic fire detection, clean agent suppression for cleanrooms
Annual revenue / production volume	Moderate; higher revenue = higher BI exposure	Accurate revenue declarations, avoid over-declaration
Deductible level	Inverse; higher deductible = lower premium	Accept higher deductibles for low-frequency risks
Export markets	High; US/EU exports increase product liability exposure	Territory-specific limits if exporting to litigious jurisdictions

Common Claims Scenarios in Malaysian Pharma Factories

Understanding real-world claims helps you identify gaps in your current coverage. These scenarios reflect the types of losses Malaysian pharma manufacturers commonly face.

Scenario	Cause	Financial Impact	Insurance Response
HVAC failure in sterile production area	Compressor burnout during heatwave	RM500K-RM2M (destroyed WIP, 4-week cleanroom re-qualification)	Machinery Breakdown + Stock + BI
Cross-contamination between production lines	Inadequate cleaning validation	RM1M-RM5M (recall + investigation + production halt)	Product Recall + BI + Product Liability
Power outage destroys cold storage vaccines	TNB grid failure, generator didn't start	RM200K-RM3M (stock value + disposal costs)	Stock Deterioration / Cold Storage
WFI system contamination	Biofilm formation in water loop	RM1M-RM5M (all injectable production halted for months)	Machinery Breakdown + MLOP
Labelling error on exported product	Wrong strength printed on carton	RM500K-RM10M (international recall + regulatory action)	Product Recall + Product Liability
Flash flood damages raw material warehouse	Monsoon flooding in industrial area	RM300K-RM2M (destroyed APIs + 3-month resourcing delay)	IAR (with flood extension) + BI

Compliance and Safety Requirements That Affect Insurance

Malaysian pharmaceutical factories operate under multiple regulatory frameworks. Non-compliance with any of these doesn't just create regulatory risk; it can void your insurance coverage or increase your premiums at renewal.

Key Regulatory Requirements

Regulation / Requirement	Enforcing Agency	Insurance Impact
GMP Compliance (Manufacturer's Licence)	NPRA	Non-compliance may void product liability claims
OSHA 1994 (Amendment 2022)	DOSH	Fines up to RM500,000; non-compliance affects WC claims
the former Factories and Machinery Act 1967 (repealed 1 Jun 2024)	DOSH	Factory registration mandatory; affects all property coverage
Fire Certificate (BOMBA)	JBPM (BOMBA)	Required for fire insurance; non-compliance can void fire claims
Environmental Quality Act 1974	DOE	Chemical waste violations create pollution liability exposure
Poisons Act 1952	Pharmacy Board	Controlled substance mishandling creates additional liability
HIRARC Assessment	DOSH	Documented risk assessment supports claims and premium negotiations

Your HIRARC assessment should specifically address pharma-specific hazards: chemical exposure to APIs, solvent handling, cleanroom ergonomic risks, and biological hazards in microbiology labs. A well-documented HIRARC not only satisfies OSHA 1994 requirements but also strengthens your position during insurance claims.

Structuring a Complete Pharma Insurance Programme

Don't buy pharma factory insurance piecemeal. A fragmented approach leaves gaps between policies and creates disputes during claims about which policy responds. Work with a specialist intermediary who understands pharma manufacturing risks to structure a programme where every policy complements the others.

Recommended Programme Structure

Layer	Policy	Key Coverage Points	Minimum Recommended Limit
1. Property	IAR + BI	Building, contents, stock, cleanroom reinstatement, 24-month BI indemnity	Full replacement value
2. Machinery	MB + MLOP	All production and QC equipment, 18-month MLOP indemnity	Replacement new value
3. Pressure Vessels	BPV	Autoclaves, boilers, compressed gas systems	Per schedule valuation
4. Electronics	EEI	HPLC, GC, mass spec, SCADA systems, data restoration	Replacement new value
5. Liability	CGL + Product Liability	Third-party claims, product-related injury, defence costs	RM5M - RM20M (depends on product type)
6. Recall	Product Contamination / Recall	Recall logistics, notification, replacement, loss of profit	RM2M - RM10M
7. Employees	Workmen Compensation	Employee injury, occupational disease (chemical exposure)	Per statutory requirements
8. Cold Chain	Stock Deterioration	Temperature excursion, refrigeration breakdown, power failure	Maximum stock value at risk

Get a comprehensive pharma insurance programme review from our specialists

Common Coverage Gaps in Pharma Factory Insurance

Even manufacturers with what they think is comprehensive coverage often have dangerous gaps. These are the most common ones we see in the Malaysian pharma sector.

Coverage Gap	Why It Exists	Potential Exposure	Solution
Cleanroom reinstatement to GMP standard	IAR covers "repair" but not GMP re-qualification costs	RM500K - RM5M per cleanroom	Endorsement for reinstatement to original GMP specification
BI indemnity period too short	Standard 12-month period, pharma needs 18-24 months	Months of uncovered revenue loss	Extend indemnity period to minimum 24 months
No product recall coverage	Recall is excluded from CGL and IAR policies	RM1M - RM10M+ per recall event	Standalone product recall / contamination policy
Temperature excursion for stock	Standard IAR excludes stock deterioration from temp change	Full cold storage inventory value	Cold storage / stock deterioration policy
Regulatory re-approval delays	BI only covers "physical damage" trigger, not regulatory delays	Extended shutdown while awaiting NPRA clearance	BI extension for regulatory re-approval period

Insurance Checklist for Malaysian Pharma Manufacturers

Use this self-assessment to identify gaps in your current coverage. If you answer "No" to any essential item, you have an uninsured exposure that needs attention.

Checklist Item	Priority	Status
IAR policy covers cleanroom reinstatement to GMP specification	Essential	Yes / No / Not Sure
Machinery Breakdown covers all production and QC equipment	Essential	Yes / No / Not Sure
BI indemnity period is at least 18 months (ideally 24)	Essential	Yes / No / Not Sure
Product liability has dedicated limit separate from CGL	Essential	Yes / No / Not Sure
Product recall / contamination insurance in place	Highly Recommended	Yes / No / Not Sure
Cold storage / stock deterioration coverage for temperature-sensitive products	Essential (if applicable)	Yes / No / Not Sure
BPV covers all autoclaves and pressurised systems	Essential (if applicable)	Yes / No / Not Sure
EEI covers QC laboratory instruments (HPLC, GC, mass spec)	Recommended	Yes / No / Not Sure
Workmen Compensation covers chemical exposure and occupational disease	Mandatory	Yes / No / Not Sure
Sum insured reflects replacement new value (not depreciated book value)	Essential	Yes / No / Not Sure

Not sure about your answers? Our specialists can review your current programme

FAQ

What insurance does a pharmaceutical factory in Malaysia need?

At minimum, you need IAR (property), Machinery Breakdown, MLOP, Business Interruption, CGL, Product Liability, and Workmen Compensation. For pharma-specific risks, add Product Recall/Contamination insurance and Cold Storage/Stock Deterioration coverage. The exact programme depends on your product type, production scale, and whether you handle temperature-sensitive products.

Does standard factory insurance cover pharmaceutical product recalls?

No. Product recall is explicitly excluded from standard IAR, fire, and CGL policies. You need a standalone Product Recall or Product Contamination insurance policy. This covers recall logistics, notification costs, product replacement, loss of profit, and crisis management expenses.

How much does pharmaceutical factory insurance cost in Malaysia?

Premiums vary significantly based on your product type, GMP compliance history, sum insured, and coverage scope. A mid-sized pharmaceutical manufacturer with RM50M-RM100M in assets can expect to spend between 0.3% to 0.8% of total sum insured annually across all policies. Biologics manufacturers and those with cold chain operations tend to pay higher premiums.

What happens to my insurance if I fail an NPRA GMP inspection?

A GMP failure itself doesn't automatically void your insurance. But if a claim arises from a condition that the GMP inspection flagged and you failed to correct, insurers may deny the claim on grounds of non-compliance or failure to maintain the insured property to reasonable standards. Maintaining clean GMP records is both a regulatory and an insurance priority.

Is product liability insurance mandatory for pharma manufacturers in Malaysia?

Product liability insurance is not legally mandatory in Malaysia. But it is commercially essential. Hospital and government tender requirements increasingly demand proof of product liability coverage. And the financial exposure from a single adverse drug reaction claim can exceed RM10M in serious cases. Going without product liability coverage is a risk most pharma manufacturers can't afford to take.

How long should my business interruption indemnity period be?

For pharmaceutical factories, a minimum of 18 months, with 24 months strongly recommended. Unlike general manufacturing where you can restart as soon as repairs are done, pharma requires equipment re-qualification (IQ/OQ/PQ), process re-validation, and NPRA re-approval before production can resume. This regulatory restart process alone can add 3-6 months beyond physical repairs.

Does my IAR policy cover cleanroom contamination?

IAR covers physical damage to the cleanroom structure and equipment. But contamination that doesn't cause physical damage (e.g., microbial contamination of air handling systems) may not trigger IAR coverage. Discuss cleanroom-specific endorsements with your insurance intermediary to ensure contamination events are covered, including the cost of decontamination and re-qualification.

What insurance covers temperature excursion damage to pharmaceutical products?

Standard IAR excludes stock deterioration from temperature change. You need a specific Stock Deterioration or Cold Storage insurance policy. This covers loss of stock value due to refrigeration breakdown, power failure, or accidental temperature excursion. Make sure the policy covers the full value of your maximum stock holding at any point.

Can I get insurance for NPRA regulatory delays after an incident?

Standard BI policies only respond to losses caused by physical damage. If your factory is physically repaired but NPRA hasn't yet re-approved your licence, the BI policy may stop paying. Some insurers offer extensions for "denial of access" or "regulatory re-approval delays" that can bridge this gap. This is an important endorsement to request for pharma-specific BI coverage.

Do I need separate insurance if I export pharmaceutical products?

Yes, if you export to markets with higher liability standards (US, EU, Australia). Your domestic product liability limit may be insufficient for claims in litigious jurisdictions. You may need territory-specific product liability coverage with higher limits and local legal defence provisions. Discuss your export markets with your insurance intermediary to ensure adequate territorial coverage.

Foundation Conclusion

Pharmaceutical manufacturing in Malaysia sits at the intersection of high-value assets, strict regulatory oversight, and significant public health responsibility. Standard factory insurance programmes leave critical gaps around product contamination, cold chain failure, and the extended business interruption timelines that GMP re-qualification demands.

Getting the right insurance programme isn't just about buying policies. It's about structuring coverage that works together so that when a contamination event, machinery failure, or regulatory shutdown happens, every financial exposure has a policy response.

Talk to our risk specialists about your pharmaceutical factory insurance programme

Disclaimer: This article provides general guidance on insurance coverage available in the Malaysian market as of February 2026. Policy terms, conditions, and availability vary by insurer. Always review your specific policy wording or consult a qualified insurance professional before making coverage decisions.